BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

823 related articles for article (PubMed ID: 28577748)

  • 21. Treatment of idiopathic membranous nephropathy.
    Hofstra JM; Fervenza FC; Wetzels JF
    Nat Rev Nephrol; 2013 Aug; 9(8):443-58. PubMed ID: 23820815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-Phospholipase A2 Receptor 1 and Anti-Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study.
    Ruggenenti P; Reinhard L; Ruggiero B; Perna A; Perico L; Peracchi T; Fidone D; Gennarini A; Benigni A; Cortinovis M; Hoxha E; Remuzzi G
    Am J Kidney Dis; 2024 May; 83(5):588-600.e1. PubMed ID: 38151224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus.
    Segarra-Medrano A; Jatem-Escalante E; Carnicer-Cáceres C; Agraz-Pamplona I; Salcedo MT; Valtierra N; Ostos-Roldán E; Arredondo KV; Jaramillo J
    Nefrologia; 2014; 34(4):491-7. PubMed ID: 25036063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of long-term repeated rituximab treatment in refractory phospholipase A2 receptor-antibody-related membranous nephropathy.
    Zhang L; Chen M; Le W; Zhang M; Tu Y; Zuo K; Chen D; Wu Y; Li S; Zeng C; Cheng Z; Xie H
    Immunotherapy; 2022 Oct; 14(15):1237-1244. PubMed ID: 36097696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The evolution of the therapeutic approach to membranous nephropathy.
    Ponticelli C; Patrizia P; Del Vecchio L; Locatelli F
    Nephrol Dial Transplant; 2021 Apr; 36(5):768-773. PubMed ID: 32206786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab in primary membranous nephropathy: first-line therapy, why not?
    Cravedi P; Remuzzi G; Ruggenenti P
    Nephron Clin Pract; 2014; 128(3-4):261-9. PubMed ID: 25427622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A novel approach to rapid induction of remission in primary membranous nephropathy].
    Dobronravov VA; Bystrova OB; Kochoyan ZS; Fomicheva EN
    Ter Arkh; 2021 Jun; 93(6):706-712. PubMed ID: 36286838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phospholipase A2 receptor positive membranous nephropathy long after living donor kidney transplantation between identical twins.
    Saito H; Hamasaki Y; Tojo A; Shintani Y; Shimizu A; Nangaku M
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():101-4. PubMed ID: 26031599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy.
    Moroni G; Depetri F; Del Vecchio L; Gallelli B; Raffiotta F; Giglio E; Brunini F; D'Amico M; Longhi S; Radice A; Messa P; Sinico RA
    Nephrol Dial Transplant; 2017 Oct; 32(10):1691-1696. PubMed ID: 27387472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary antiphospholipid syndrome associated with anti-phospholipase A2 receptor antibody-positive membranous nephropathy.
    Teisseyre M; Perrochia H; Reboul P; Cariou S; Renaud S; Aglae C; Moranne O
    BMC Nephrol; 2020 May; 21(1):196. PubMed ID: 32448215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
    Ramachandran R; Hn HK; Kumar V; Nada R; Yadav AK; Goyal A; Kumar V; Rathi M; Jha V; Gupta KL; Sakhuja V; Kohli HS
    Nephrology (Carlton); 2016 Feb; 21(2):139-46. PubMed ID: 26205759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrinogen-albumin ratio predicts treatment response in phospholipase A2 receptor-associated membranous nephropathy with nephrotic syndrome.
    Duan S; Chen S; Chen C; Lu F; Pan Y; Lu Y; Li Q; Liu S; Zhang B; Mao H; Xing C; Yuan Y
    Ren Fail; 2024 Dec; 46(1):2359024. PubMed ID: 38832491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibodies against M-Type Phospholipase A2 Receptor May Predict Treatment Response and Outcome in Membranous Nephropathy.
    Qu Z; Zhang MF; Cui Z; Wang J; Wang M; Zhang YM; Wang F; Wang X; Meng LQ; Cheng XY; Liu G; Zhao MH
    Am J Nephrol; 2018; 48(6):438-446. PubMed ID: 30472708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study.
    Huang Y; Zhou J; Zhou K; Huang B; Xue J; Zhang X; Liu B; Zhang Z; Zhou L; Cai T; Zhang Y; Hu Z; Wang L; Liu X
    PeerJ; 2022; 10():e14193. PubMed ID: 36248712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-phospholipase A2 Receptor Antibody and Immunosuppression in Membranous Nephropathy: More Evidence for Pathogenicity of Anti-phospholipase A2 Receptor Autoantibodies.
    Brenchley PE
    J Am Soc Nephrol; 2015 Oct; 26(10):2308-11. PubMed ID: 25804283
    [No Abstract]   [Full Text] [Related]  

  • 36. PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system.
    Hoxha E; Harendza S; Pinnschmidt H; Panzer U; Stahl RA
    PLoS One; 2014; 9(10):e110681. PubMed ID: 25313791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: A long-term follow-up.
    Zhou XJ; Zhou FD; Wang SX; Zhao MH
    Medicine (Baltimore); 2018 Jun; 97(25):e11184. PubMed ID: 29924035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of primary membranous nephropathy: where are we now?
    Angioi A; Lepori N; López AC; Sethi S; Fervenza FC; Pani A
    J Nephrol; 2018 Aug; 31(4):489-502. PubMed ID: 28875476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma exchange and rituximab treatments in primary membranous nephropathy combined with crescentic glomerulonephritis: A case report.
    Lu H; Cui Z; Zhou XJ; Jin QZ; Yu XJ; Wang SX; Wang Y; Zhou FD; Zhao MH
    Medicine (Baltimore); 2019 May; 98(18):e15303. PubMed ID: 31045764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.
    Segarra-Medrano A; Jatem-Escalante E; Quiles-Pérez MT; Salcedo MT; Arbós-Via MA; Ostos H; Valtierra N; Carnicer-Cáceres C; Agraz-Pamplona I
    Nefrologia; 2014 May; 34(3):353-9. PubMed ID: 24798555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.